Skip to main content
. Author manuscript; available in PMC: 2018 May 15.
Published in final edited form as: J Immunol. 2017 Mar 29;198(10):4129–4139. doi: 10.4049/jimmunol.1601722

Figure 6. Impact of G-CSF treatment on IRF8 expression and myeloid progenitor cell frequencies.

Figure 6

Recombinant G-CSF was administered (10μg/mouse) for five consecutive days in IRF8-EGFP mice. Mice were rested for 24 hours, after which bone marrow was collected and analyzed for the indicated myeloid progenitor subset, as in Fig 1. (A–B) Total GMP frequencies are shown in control- or G-CSF-treated mice, along with a breakdown of the different myeloid progenitor subsets. IRF8 expression (C) and GP:MP ratio (D) were also analyzed. Data representative of two experiments (n=5 for all groups).